Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2 is a research paper published in International Journal of Molecular Sciences (2024). On theSindex it has a DataRank of 0. It has been cited 7 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Defense Threat Reduction Agency (DTRA)
Grant: CBM.THROX.03.10.RD.006
Defense Threat Reduction Agency (DTRA)
Grant: W81XWH-07-1-0565
Defense Threat Reduction Agency (DTRA)
Grant: CA203420
Defense Threat Reduction Agency (DTRA)
Grant: CA228813
Defense Threat Reduction Agency (DTRA)
Grant: DK120130
Defense Threat Reduction Agency (DTRA)
Grant: DK125126
Defense Threat Reduction Agency (DTRA)
Grant: AI162182
National Institutes of Health
Grant: 5R44DK125126-03
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes
National Institutes of Health
Grant: 3R43CA203420-01S1
Targeting galectin-3 for prostate cancer therapy
National Institutes of Health
Grant: 1R43DK120130-01
Targeting galectin-3 for treatment of NASH mediated fibrosis
National Institutes of Health
Grant: 1R43AI162182-01A1
Targeting galectin-3 to intervene COVID-19
National Institutes of Health
Grant: 1R43CA228813-01A1
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
NCI NIH HHS
Grant: R43 CA203420
NIDDK NIH HHS
Grant: R43 DK120130
NIAID NIH HHS
Grant: R43 AI162182
NIH HHS
Grant: 5R43AI162182-02A1
NIDDK NIH HHS
Grant: R44 DK125126
NCI NIH HHS
Grant: R43 CA228813
NIDDK NIH HHS
Grant: R43 DK125126
FWCI
1.06
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals